Concepedia

Rebecca L. Lloyd

RL

5

Publications

336

Citations

5

H-Index

2019

Active since

Affiliations

AstraZeneca (United Kingdom)(Current)

The Gurdon Institute

University of Cambridge

Rebecca L. Lloyd is an author at AstraZeneca (United Kingdom) specializing in cancer genetics, genome editing, and cancer research.

Top concepts

Publications per year

2019–2023

5

Publications

5

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells

Rebecca L. Lloyd, Paul W.G. Wijnhoven, Antonio Ramos‐Montoya et al. · Oncogene · 2020 · 179 citations · Full text

Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress

Rebecca L. Lloyd, Václav Urban, Francisco Muñoz‐Martínez et al. · Nucleic Acids Research · 2021 · 52 citations · Full text

, , +20

Distinct Molecular Trajectories Converge to Induce Naive Pluripotency

Hannah T. Stuart, Giuliano Giuseppe Stirparo, Tim Lohoff et al. · Cell stem cell · 2019 · 47 citations · Full text

Understanding Intracellular Biology to Improve mRNA Delivery by Lipid Nanoparticles

Morag R. Hunter, Lili Cui, Benjamin T. Porebski et al. · Small Methods · 2023 · 37 citations · Full text

Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development

Sonja J. Gill, Paul W.G. Wijnhoven, Jacqueline H. L. Fok et al. · Molecular Cancer Therapeutics · 2021 · 21 citations · Full text

Rows per page

1–5 of 5